research-intel
Server Details
Research GTM triggers: new NIH grants by PI/institution and new clinical trials by sponsor/phase.
- Status
- Healthy
- Last Tested
- Transport
- Streamable HTTP
- URL
Glama MCP Gateway
Connect through Glama MCP Gateway for full control over tool access and complete visibility into every call.
Full call logging
Every tool call is logged with complete inputs and outputs, so you can debug issues and audit what your agents are doing.
Tool access control
Enable or disable individual tools per connector, so you decide what your agents can and cannot do.
Managed credentials
Glama handles OAuth flows, token storage, and automatic rotation, so credentials never expire on your clients.
Usage analytics
See which tools your agents call, how often, and when, so you can understand usage patterns and catch anomalies.
Tool Definition Quality
Average 3.4/5 across 5 of 5 tools scored.
Tools are mostly distinct. delta_digest and new_funding both retrieve new items but target different use cases (BD teams vs GTM trigger). Descriptions help differentiate. No severe overlap.
All names use lowercase underscores. Consistency is good overall, but grammatical patterns vary: verb_noun (search_records), adjective_noun (new_funding), noun_noun (entity_watch). Minor inconsistency.
5 tools is appropriate for the domain. Each tool serves a clear purpose without redundancy.
Core operations for monitoring and searching grants/trials are covered. Missing a dedicated tool for retrieving a single record's full details, but search_records can function as such. Minor gap.
Available Tools
5 toolsdelta_digestBInspect
New grants + new trials in a filter over the last N days (the weekly-digest payload). Best for BD teams.
| Name | Required | Description | Default |
|---|---|---|---|
| ic | No | NIH Institute/Center abbreviation, e.g. 'NCI'. | |
| pi | No | Principal investigator name substring. | |
| days | No | Lookback days (default 7). | |
| kind | No | 'grant' or 'trial' to restrict. | |
| phase | No | Trial phase substring, e.g. 'PHASE2'. | |
| state | No | 2-letter US state of the org/site. | |
| topic | No | Canonical topic slug, e.g. 'oncology', 'neuroscience'. | |
| keyword | No | ||
| sponsor | No | Trial sponsor name substring. | |
| maxAmount | No | ||
| minAmount | No | ||
| institution | No | Institution name substring. | |
| sponsorClass | No | INDUSTRY | NIH | OTHER_GOV | OTHER | INDIV. |
Tool Definition Quality
Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?
No annotations are provided, so the description must fully disclose behavioral traits. It only states the output type (new grants and trials) but omits critical details like whether results are paginated, how 'new' is defined (e.g., by creation date), any rate limits, or side effects. This leaves significant ambiguity for an AI agent.
Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.
Is the description appropriately sized, front-loaded, and free of redundancy?
The description is very concise (one sentence plus audience note) and front-loaded with the core action. However, given 13 parameters, it could be slightly more detailed without losing conciseness.
Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.
Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?
The tool has 13 optional parameters and no output schema. The description fails to mention output format, ordering, limits, pagination, or how 'new' is determined. Compared to sibling 'whats_changed_since', it lacks clarity on what differentiates this digest from other change-tracking tools.
Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.
Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?
The schema covers 77% of parameters with descriptions, so the baseline is 3. The tool description does not add any parameter-specific context beyond what the schema provides, missing an opportunity to highlight key filters like 'kind' or 'days'.
Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.
Does the description clearly state what the tool does and how it differs from similar tools?
The description clearly states what the tool does: it returns 'New grants + new trials' filtered over a number of days, and specifies the use case as 'weekly-digest payload' for BD teams. This differentiates it from sibling tools like 'search_records' (general search) and 'new_funding' (likely broader).
Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.
Does the description explain when to use this tool, when not to, or what alternatives exist?
The description provides context by stating 'Best for BD teams' and 'weekly-digest payload', implying it is used for periodic reporting. However, it does not explicitly specify when not to use this tool or mention any alternative tools among the siblings.
Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.
entity_watchBInspect
Recent funding/trial events for one institution, PI, sponsor, or topic. Use to enrich an account or check a competitor.
| Name | Required | Description | Default |
|---|---|---|---|
| type | Yes | 'institution' | 'pi' | 'sponsor' | 'topic'. | |
| value | Yes | The entity name/value. |
Tool Definition Quality
Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?
No annotations are provided, so the description must fully disclose behavior. It mentions 'recent' events but does not specify the time range, output structure, pagination, or any potential side effects. This leaves the agent with incomplete understanding of the tool's behavior.
Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.
Is the description appropriately sized, front-loaded, and free of redundancy?
The description is two sentences and directly conveys purpose and usage context. It is efficient with no redundant information, though the second sentence could be slightly more specific.
Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.
Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?
The description adequately covers the tool's purpose and how to use it for the two parameters, but it omits details about return format, error conditions, and the definition of 'recent.' Given no output schema, more completeness is warranted.
Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.
Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?
Schema coverage is 100%, so the schema already documents both parameters. The description restates the entity types but adds no additional semantic meaning beyond the schema's descriptions. Baseline of 3 is appropriate.
Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.
Does the description clearly state what the tool does and how it differs from similar tools?
Description clearly states the tool returns 'Recent funding/trial events' for a specific entity. It provides concrete use cases ('enrich an account or check a competitor') and specifies the four entity types. While it distinguishes from siblings in intent, it does not explicitly compare to sibling tools like delta_digest or new_funding.
Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.
Does the description explain when to use this tool, when not to, or what alternatives exist?
The description suggests when to use ('enrich an account or check a competitor') but lacks explicit guidance on when not to use it or alternatives among siblings. The context is implied rather than explicit.
Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.
new_fundingAInspect
THE GTM-trigger tool. Return the newest NIH grants and newly-registered clinical trials in a territory — the highest-intent buying signal in life-sciences sales (a newly-funded lab has budget and is choosing vendors now). Filter by institution, PI, sponsor, topic, state, IC, phase.
| Name | Required | Description | Default |
|---|---|---|---|
| ic | No | NIH Institute/Center abbreviation, e.g. 'NCI'. | |
| pi | No | Principal investigator name substring. | |
| kind | No | 'grant' or 'trial' to restrict. | |
| limit | No | Max per kind (default 50). | |
| phase | No | Trial phase substring, e.g. 'PHASE2'. | |
| state | No | 2-letter US state of the org/site. | |
| topic | No | Canonical topic slug, e.g. 'oncology', 'neuroscience'. | |
| keyword | No | ||
| sponsor | No | Trial sponsor name substring. | |
| maxAmount | No | ||
| minAmount | No | ||
| institution | No | Institution name substring. | |
| sponsorClass | No | INDUSTRY | NIH | OTHER_GOV | OTHER | INDIV. |
Tool Definition Quality
Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?
No annotations are provided, so the description must carry the full burden. It correctly indicates a read operation (returns data) but does not disclose any behavioral traits such as rate limits, authorization needs, or pagination behavior, which is a notable gap.
Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.
Is the description appropriately sized, front-loaded, and free of redundancy?
The description is exceptionally concise with two sentences. The first sentence front-loads the core purpose and value proposition ('highest-intent buying signal'), and the second lists filters efficiently. No wasted words.
Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.
Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?
Given 13 parameters and no output schema, the description leaves gaps: it doesn't explain the return structure, pagination, or how results are ordered. For a tool that returns many records, this is a significant omission.
Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.
Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?
Schema description coverage is 77%, already providing decent parameter documentation. The description adds context about filtering by 'institution, PI, sponsor, topic, state, IC, phase' but does not significantly enhance clarity beyond the schema. Baseline 3 is appropriate.
Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.
Does the description clearly state what the tool does and how it differs from similar tools?
The description clearly states the tool returns 'the newest NIH grants and newly-registered clinical trials in a territory', specifying both verb and resource. It explicitly distinguishes itself as a 'GTM-trigger tool' for life-sciences sales, differentiating from sibling tools like delta_digest or search_records.
Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.
Does the description explain when to use this tool, when not to, or what alternatives exist?
The description provides strong context on when to use (high-intent buying signal for sales) but does not explicitly state when not to use or compare to alternatives. It implies usage for initial outreach but lacks direct exclusion criteria.
Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.
search_recordsAInspect
Ad-hoc search/enrichment over snapshotted grants + trials by any filter (keyword, sponsorClass, topic, $ range).
| Name | Required | Description | Default |
|---|---|---|---|
| ic | No | NIH Institute/Center abbreviation, e.g. 'NCI'. | |
| pi | No | Principal investigator name substring. | |
| kind | No | 'grant' or 'trial' to restrict. | |
| limit | No | Default 50. | |
| phase | No | Trial phase substring, e.g. 'PHASE2'. | |
| state | No | 2-letter US state of the org/site. | |
| topic | No | Canonical topic slug, e.g. 'oncology', 'neuroscience'. | |
| keyword | No | ||
| sponsor | No | Trial sponsor name substring. | |
| maxAmount | No | ||
| minAmount | No | ||
| institution | No | Institution name substring. | |
| sponsorClass | No | INDUSTRY | NIH | OTHER_GOV | OTHER | INDIV. |
Tool Definition Quality
Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?
No annotations are provided, so the description carries full burden. It discloses that the data is 'snapshotted' (not real-time), but does not mention read-only nature, authentication needs, or side effects. Some behavioral context but limited.
Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.
Is the description appropriately sized, front-loaded, and free of redundancy?
The description is a single, front-loaded sentence with key verbs and resource. It is efficient but could be slightly more structured by grouping filter types.
Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.
Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?
With 13 parameters and no output schema or annotations, the description is too brief. It does not explain return format, pagination (despite a limit parameter), or what 'enrichment' entails. More details are needed for a complex search tool.
Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.
Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?
Schema description coverage is 77% (high), so baseline is 3. The description adds high-level filter categories but does not compensate for the 3 undocumented parameters (keyword, maxAmount, minAmount). The schema already documents most parameters.
Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.
Does the description clearly state what the tool does and how it differs from similar tools?
The description clearly states the tool performs ad-hoc search/enrichment over snapshotted grants and trials, listing example filters (keyword, sponsorClass, topic, $ range). It distinguishes from siblings by specifying the scope and flexibility.
Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.
Does the description explain when to use this tool, when not to, or what alternatives exist?
The description implies usage for ad-hoc searching but does not explicitly state when to use this tool versus alternatives like delta_digest or whats_changed_since. No exclusions or when-not guidance is provided.
Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.
whats_changed_sinceBInspect
Return grants/trials that are NEW or MODIFIED since a cursor token (cursor = your bookmark / CRM-sync point). Pass the cursor from a prior call to get only changes since then. Same filters as new_funding.
| Name | Required | Description | Default |
|---|---|---|---|
| ic | No | NIH Institute/Center abbreviation, e.g. 'NCI'. | |
| pi | No | Principal investigator name substring. | |
| kind | No | 'grant' or 'trial' to restrict. | |
| limit | No | ||
| phase | No | Trial phase substring, e.g. 'PHASE2'. | |
| state | No | 2-letter US state of the org/site. | |
| topic | No | Canonical topic slug, e.g. 'oncology', 'neuroscience'. | |
| cursor | No | Opaque cursor from a previous response; omit for first call. | |
| keyword | No | ||
| sponsor | No | Trial sponsor name substring. | |
| maxAmount | No | ||
| minAmount | No | ||
| institution | No | Institution name substring. | |
| sponsorClass | No | INDUSTRY | NIH | OTHER_GOV | OTHER | INDIV. |
Tool Definition Quality
Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?
With no annotations, the description carries the full burden. It discloses that the tool returns new/modified records based on a cursor, implying it is a read operation with state tracking. However, it does not mention any side effects, authentication needs, rate limits, or other behavioral traits, leaving significant gaps for an agent assessing safety.
Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.
Is the description appropriately sized, front-loaded, and free of redundancy?
The description is concise at three sentences, front-loading the purpose and cursor usage. It avoids fluff but could be slightly more structured to separate usage guidance from filter reference.
Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.
Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?
Given 14 parameters, no output schema, and no annotations, the description is incomplete. It explains the cursor mechanism well but does not describe return values, pagination, limits, or any caveats. The cross-reference to new_funding helps but relies on the agent knowing that tool's capabilities.
Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.
Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?
Schema description coverage is 71% (high), so the baseline is 3. The description adds value by stating 'Same filters as new_funding,' which cross-references another tool for context. However, it does not explain individual parameters beyond what the schema already provides, and the reference assumes knowledge of new_funding.
Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.
Does the description clearly state what the tool does and how it differs from similar tools?
The description clearly states the tool returns grants/trials that are NEW or MODIFIED since a cursor token, with a specific verb and resource. However, it does not explicitly differentiate from sibling tools like delta_digest or entity_watch, relying on the cursor mechanism for implicit differentiation.
Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.
Does the description explain when to use this tool, when not to, or what alternatives exist?
The description instructs to pass the cursor from a prior call and notes that filters are the same as new_funding, providing some context on when to use. But it lacks explicit when-not-to-use instructions or alternative tools for different scenarios (e.g., full data retrieval).
Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.
Claim this connector by publishing a /.well-known/glama.json file on your server's domain with the following structure:
{
"$schema": "https://glama.ai/mcp/schemas/connector.json",
"maintainers": [{ "email": "your-email@example.com" }]
}The email address must match the email associated with your Glama account. Once published, Glama will automatically detect and verify the file within a few minutes.
Control your server's listing on Glama, including description and metadata
Access analytics and receive server usage reports
Get monitoring and health status updates for your server
Feature your server to boost visibility and reach more users
For users:
Full audit trail – every tool call is logged with inputs and outputs for compliance and debugging
Granular tool control – enable or disable individual tools per connector to limit what your AI agents can do
Centralized credential management – store and rotate API keys and OAuth tokens in one place
Change alerts – get notified when a connector changes its schema, adds or removes tools, or updates tool definitions, so nothing breaks silently
For server owners:
Proven adoption – public usage metrics on your listing show real-world traction and build trust with prospective users
Tool-level analytics – see which tools are being used most, helping you prioritize development and documentation
Direct user feedback – users can report issues and suggest improvements through the listing, giving you a channel you would not have otherwise
The connector status is unhealthy when Glama is unable to successfully connect to the server. This can happen for several reasons:
The server is experiencing an outage
The URL of the server is wrong
Credentials required to access the server are missing or invalid
If you are the owner of this MCP connector and would like to make modifications to the listing, including providing test credentials for accessing the server, please contact support@glama.ai.
Discussions
No comments yet. Be the first to start the discussion!
Related MCP Servers
- AlicenseBqualityDmaintenanceEnables comprehensive medical research by querying and analyzing data across ClinicalTrials.gov, PubMed, and FDA databases with AI-enhanced cross-database insights, risk assessments, and competitive intelligence.Last updated1311MIT
- Alicense-qualityAmaintenancePharmaceutical R\&D Pipeline Intelligence for AI Agents — Clinical trials, FDA approvals, drug information & publications in one MCP server.Last updated3MIT
- Flicense-qualityBmaintenanceUS patent search, full-text retrieval, claim extraction, citation graph, and weekly grant alerts for R\&D, biotech, and IP-law audiences.Last updated
- Alicense-qualityCmaintenanceAccess data on every NIH-funded research project. Free and no authentication required.Last updated4MIT